SRTA (Strata Critical Medical) Moat Score: 2/10 (As of Jul. 02, 2026)


SRTA Strata Critical Medical Inc SRTA
70 GF Score
Price $5.41
GF Value $4.47
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strata Critical Medical Moat Score?

Strata Critical Medical SRTA +2.27% 70 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates SRTA with a GF Score™ of 70/100 and a GF Value™ of $4.47 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Strata Critical Medical ranks better than 79.38% on this metric.

Strata Critical Medical has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Strata Critical Medical has No Moat: Strata Critical Medical lacks significant competitive advantages, with minimal market share and no strong brand presence. The medical device industry is highly competitive, and the company has limited intellectual property, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Strata Critical Medical might have No Moat - Very weak/transient advantages.

Strata Critical Medical  (NAS:SRTA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Strata Critical Medical Moat Score Related Terms

SRTA vs CYH, CCRN, AUNA: Moat Score Comparison

For the Medical Care Facilities subindustry, Strata Critical Medical's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Critical Medical Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Moat Score distribution charts can be found below:

* The bar in red indicates where Strata Critical Medical's Moat Score falls into.


SRTA
70GF Score
Strata Critical Medical Inc SRTA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Strata Critical Medical (SRTA) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Strata Critical Medical ranks #140 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 20.6%.
Is Strata Critical Medical's Moat Score too high?
Strata Critical Medical's current Moat Score is 2. Based on the distribution chart, Strata Critical Medical ranks #140 out of 679 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Strata Critical Medical has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's Moat Score compare to CYH and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Strata Critical Medical ranks #140 out of 679 companies for Moat Score. This places Strata Critical Medical in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Strata Critical Medical's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.47, compared to a current price of $5.41 — trading 21% above its estimated fair value. The current Moat Score is 2. Strata Critical Medical's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Critical Medical (SRTA) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued. The current stock price of $5.41 is trading 21% above its estimated GF Value™ of $4.47. GuruFocus considers Strata Critical Medical to be Modestly Overvalued.

Key valuation signals for SRTA:

  • Moat Score: 2
  • GF Value™: $4.47 vs. price of $5.41 (21% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Critical Medical Business Description

Address 31 Hudson Yards, 14th Floor, New York, NY, USA, 10001
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
70GF Score

Get the complete analysis for SRTA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.41
Price
$4.47
GF Value